Statin-fibrate combination therapy for hyperlipidaemia: A review

Current Medical Research and Opinion

Volumn 19, Issue 3, 2003, Pages 155-168

  Wierzbicki, A S ^a   Mikhailidis, D P ^b   Wray, R ^c   Schachter, M ^d   Cramb, R ^e   Simpson, W G ^f   Byrne, C B ^g  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c St Leonards on Sea   (United Kingdom)

^d ST MARY S HOSPITAL   (United Kingdom)

^e QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^f ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^g University Hospital Southampton   (United Kingdom)

Author keywords

Combination therapy; Fibrate; HMG CoA reductase inhibitor; Review; Statin

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CIPROFIBRATE; CLOFIBRATE; CYCLOSPORIN; CYTOCHROME P450; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PRAVASTATIN; PROTEINASE INHIBITOR; SIMVASTATIN; TRIACYLGLYCEROL;

CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG INDICATION; HALF LIFE TIME; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; KIDNEY FUNCTION; LIVER FUNCTION; LOW DRUG DOSE; MONOTHERAPY; MYOSITIS; REVIEW; RHABDOMYOLYSIS; STROKE; THYROID FUNCTION; TITRIMETRY;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CEREBROVASCULAR ACCIDENT; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPERLIPIDEMIAS;

EID: 0013301537     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125001668     Document Type: Review

References (132)

1. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97
2. Kannel WB, Castelli WP, Gordon T, McNamara P. Serum cholesterol lipoproteins and risk of coronary heart disease: the Framingham Study. Ann Intern Med 1971;74:1-12
3. Assman G, Schulte H. Role of triglycerides in coronary artery disease: lessons from the prospective cardiovascular Munster Study. Am J Cardiol 1992;70:10H-13H
4. Ahmad I, Miller M. Triglycerides and coronary heart disease: a global perspective. J Cardiovasc Risk 2000;7:303-7
5. Criqui MH, Hess G, Cohn R, et al. Plasma triglyceride level and mortality form coronary heart disease. N Engl J Med 1993;328:1220-5
6. Roche HM, Gibney MJ. The impact of postprandial lipemia in accelerating atherothrombosis. J Cardiovasc Risk 2000;7:3172-4
7. Ooi TC, Ooi DS. The atherogenic significance of an elevated plasma triglyceride level. Crit Rev Clin Lab Sci 1998;35:489-516
8. Packard CJ, Shepherd J. Physiology of the lipoprotein transport system: an overview of lipoprotein metabolism. In Betteridge DJ, Illingworth DR, Shepherd J, eds. Lipoproteins in Health and Disease. London: Arnold, 1999:17-31
9. Austin MA. Low-density lipoprotein subclass phenotypes, triglycerides and coronary heart disease. In Betteridge DJ, Illingworth DR, Shepherd J, eds. Lipoproteins in Health and Disease. London: Arnold, 1999:611-19
10. Hodis HN, Mack WJ. Triglyceride-rich lipoproteins and progression of atherosclerosis. Eur Heart J 1998;19(Suppl. A):A40-A44
11. Lamarche B, Tcherhof A, Moorjani S, et al. Small dense lowdensity lipoprotein particles as a predictor of risk of ischaemic heart disease in men. Circulation 1997;95:69-75
12. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996;276:875-81
13. Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997;95:1-4
14. Gervaise N, Garrigue GN, Lasfargues G, Lecomte P. Triglycerides, apo C3 and LpB:C3 and cardiovascular risk in type II diabetes. Diabetologia 2000;43:703-8
15. Hokannson JE, Austin MA. Plasma triglyceride is a risk factor for cardiovascular disease independent of high-density-lipoprotein cholesterol level: a meta-analysis of population-based studies. J Cardiovasc Risk 1996;3:212-19
16. Wierzbicki AS, Mikhailidis DP, Wray R. Mixed hyperlipidemia. Am J Cardiovasc Pharmacol 2001;1:327-36
17. Kreissberg RA. Diabetic dyslipidemia. Am J Cardiol 1998;82:67U-73U
18. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34
19. Godsland I, Stevenson JC. Insulin resistance. Lancet 1995;345:100-3
20. Garg A. Insulin resistance in the pathogenesis of dyslipidemia. Diabetes Care 1996;19:387-9
21. Laasko M. Epidemiology of diabetic dyslipidaemia. Diabetes Rev 1995;3:463-524
22. Matthaei S., Stumholl M, Kellerer M, Haring H-U. Pathophysiology, pharmacology and treatment of insulin resistance. Endocrinol Rev 2000;21:585-618
23. Ounpau S, Anand S, Yusuf S. The impending global epidemic of cardiovascular disease. Eur Heart J 2000;21:880-2
24. Vega GL, Grundy SM. Effects of statins on metabolism of apoB-containing lipoproteins in hypertriglyceridemic men. Am J Cardiol 1998;81:36B-42B
25. Moberly JB, Attman PO, Samuelsson O, Johansson AC, KnightGibson C, Alaupovic P. Apolipoprotein C-III, hypertriglyceridemia and triglyceride-rich lipoproteins in uremia. Mineral Electrolyte Metab 1999;25:258-62
26. Oluwatoyin M, Falusi MD, Aberg JA. HIV and cardiovascular risk factors. AIDS Reader 2001;11:263-8
27. Moghadasian MH, Mancini GB, Frohlich JJ. Pharmacotherapy of hypercholesterolaemia: statins in clinical practice. Expert Opin Pharmacother 2000;1:683-95
28. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridaemia. Am J Cardiol 1998;81:66B-69B
29. Wierzbicki AS, Lumb PJ, Chik G, Crook MA. High-density lipoprotein cholesterol and triglyceride response with simvastatin vs. atorvastatin in familial hypercholesterolemia. Am J Cardiol 2000;86:547-9
30. Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, lowdensity lipoprotein subfraction distribution and hemorheological parameters in type 2 diabetes mellitus with mixed hyperlipidemia. Am J Cardiol 2001;87:44-8
31. Mikhailidis DP, Wierzbicki AS. HDL Cholesterol and the treatment of coronary heart disease. Curr Med Res Opin 2000;16:139-46
32. Fruchart JC, Brewer HB Jr, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am J Cardiol 1998;81:912-17
33. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 2000;129:823-34
34. Gervois P, Torra IP, Fruchart JC, Staels B. Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med 2000;38:3-11
35. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-93
36. Fruchart J-C, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001;3:83-92
37. Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPARgamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Med 2001;7:53-8
38. Inoue I, Goto S, Mizotani K, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin 1-beta, interleukin-6, cyclooxygenase 2 and p22phox by regulation of peroxisome proliferatoractivated receptor alpha (PPAR-alpha) in primary endothelial cells. Life Sci 2000;67:863-76
39. Paolisso G, Barbagallo M, Petrella G, et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 2000;150:121-7
40. Freeman DM, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Project. Circulation 2001;103:357-62
41. Idzior-Walus B, Sieradzki J, Rostworowski W, Zdzienicka A, Kawalec E, Wojcik J, Zarnecki A, Blane G. Effects of co-micronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest 2000;30:871-8
42. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998;34:155-62
43. Spence JD. Metabolism of fibric acid derivatives. Clin Pharmacokinet 1998;34:419-20
44. Jeng CY, Sheu WH, Fuh MM, Shieh SM, Chen YD, Reaven GM. Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrations. J Clin Endocrinol Metab 1996;81:2550-3
45. Dujovne CA, Moriarty PM. Clinical pharmacologic concepts for the rational selection and use of drugs for the management of dyslipidemia. Clin Ther 1996;18:392-410
46. Farnier M, Picard S. Diabetes: statins, fibrates or both? Curr Atheroscler Rep 2001;3:19-28
47. Tannous M, Cheung R, Vignini A, Mutus B. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. Thromb Haemost 1999;82:1390-4
48. Zambrana JL, Velasco F, Castro P, Concha M, Valles F, Montilla P, Jiminez-Pereperez JA, Lopez-Miranda J, Perez-Jimenez F. Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipidemic heart transplant patients. Am J Cardiol 1997;80:836-40
49. Cortellaro M, Cofrancesco E, Boschetti C, et al. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, tplasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment. Thromb Haemost 2000;83:549-53
50. Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernandez JA. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 1999;103:219-27
51. Crook MA, Ch'ng SI, Lumb P. Serum apolipoprotein H and its relationship to lipids and other apolipoproteins in normal human men and women. Blood Coag Fibrinolysis 1999;10:197-200
52. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001;103:1191-3
53. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Longterm effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-5
54. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Caatellani LW, Reddy S, Shih D, Shi W, Watson AD, van Lenten BJ, Vora D, Fogelman AM. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001;21:481-8
55. Zwacka TP, Hornbach V, Torzewski J. C-reactive protein-mediated lipoprotein uptake by macrophages. Circulation 2001;103:1194-7
56. Wilmink HW, Twickler MB, Bamga JD, Dallinga-Thie GM, Eeltink H, Erkelenes DW, Rabelink DJ, Stoes ES. Effect of statin versus fibrate on post-prandial endothelial dysfunction: role of remnant-like particles. Cardiovasc Res 2001;50:577-82
57. Simons LA, Sullivan D, Simons J, Celermajer DS. Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia. Atherosclerosis 1998;137:197-203
58. Holm T, Andreassen AK, Ueland T, Kjekshus J, Froland SS, Kjekshus E, Simonsen S, Aukrust P, Gullestad L. Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am J Cardiol 2001;87:815-18
59. Wood D, Durrington P, Poulter N, McInnes G, Rees A, Wray R on behalf of the Societies Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(Suppl. 2):S1-29
60. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-18
61. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-45
62. Tenkanen L, Manttari M, Mattinen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the Helsinki Heart Study. Circulation 1995;92:1779-85
63. The BIP study group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarct Prevention (BIP) Study. Circulation 2000;102:21-7
64. Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators. Lancet 1980;2:379-85
65. Huttunen JK, Heinonen OP, Manninen V, Koskinen P, Hakulinen T, Teppo L, Manttari M, Frick MH. The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J Intern Med 1994;235:31-9
66. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997;20:614-20
67. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Circulation 1998;98:2513-19
68. Durrington P. Statins and fibrates in the management of diabetic dyslipidemia. Diabet Med 1997;14:513-16
69. Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the prospective pravastatin pooling project. Circulation 2000;102:1893-1900
70. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of HMG-CoA reductase inhibitors. Clin Pharmacokinetics 1997;32:403-25
71. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 2002;128:159-68
72. Smit JW, Bar PR, Geerdink RA, Erkelens DW. Heterozygous familial hypercholesterol-aemia is associated with pathological exercise-induced leakage of muscle proteins, which is not aggravated by simvastatin therapy. Eur J Clin Invest 1995;25:79-84
73. Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 2000;15:1993-9
74. Abdul-Ghaffar NU, el-Sonbaty MR. Pancreatitis and rhabdomyolysis associated with lovastatin-gemfibrozil therapy. J Clin Gastroenterol 1995;21:340-1
75. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharm Ther 2001;69:340-5
76. Oldemeyer JB, Lund RJ, Koch M, Meares AJ, Dunlay R. Rhabdomyolysis and acute renal failure after changing statinfibrate combinations. Cardiology 2000;94:127-8
77. Dujovne CA. Drug interactions of lipid-altering drugs. Drug Safety 1998;19:355-71
78. Beggs PW, Clark DW, Williams SM, Coulter DM. A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand intensive medicines monitoring programme (1MMP). Br J Clin Pharmacol 1999;47:99-104
79. Pan WJ, Gustavson LE, Achari R, Riesre MJ, Ye X, Gutterman C, Wallin BA. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharm 2000;40:316-23
80. Tikannen MJ. Statins: within group comparisons, statin escape and combination therapy. Curr Opin Lipidol 1996;7:385-8
81. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of efficacy and safety. Eur Heart J 1995;16:5-13
82. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 1998;352:1031-2
83. Wierzbicki AS, Reynolds TM, Crook MA, Tatler J, Peters BS. Lipid lowering therapy in patients with HIV infection. Lancet 1998;351:1782
84. Kehely A, MacMahon M, Barbir M, Wray R, Hunt BJ, Prescott RJ, Thompson GR. Combined bezafibrate and simvastatin treatment for mixed hyperlipidemia. Q J Med 1995;88:421-7
85. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Diangelos TP, Carina MV, Kranitsas DF, Kontopoulos AG. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997;80:608-13
86. Athyros VG, Papgeorgiou AA, Kontopoulos AG. Statin-fibrate combinations in patients with combined hyperlipidemia. Atherosclerosis 2001;155:263-4
87. Eliav O, Schurr D, Pfister P, Friedlander Y, Leitersdorf E. Highdose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia. Am J Cardiol 1995;76A-79A
88. Ellen RL, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998;81:60B-65B
89. Feher MD, Foxton J, Banks D, Lant AF, Wray R. Long-term safety of statin-fibrate combination therapy in the management of hypercholesterolaemia inpatients with coronary artery disease. Br Heart J 1995;74:14-17
90. Gavish D, Leibovitz E, Shapira I, Rubinstein A. Bezafibrate and simvastatin combination therapy for diabetic dyslipidemia: efficacy and safety. J Intern Med 2000;247:563-9
91. Kayikcioglu M, Ozerkan F, Soydan I. Effectiveness and safety of alternate day simvastatin and fenofibrate on mixed hyperlipidemia. Am J Cardiol 1999;83:1135-7
92. Kiortisis DN, Millionis H, Bairaktari E, Elisaf MS. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia. Eur J Clin Pharm 2000;56:631-5
93. Papadakis JA, Ganotakis ES, Jagroop IA, Winder AF, Mikhailids DP. Statin + fibrate combination therapy: fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int J Cardiol 1999;69:237-44
94. Pauciullo P, Borgnino C, Paoletti R, Mariani M, Mancini M. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis 2000;150:429-36
95. Speiker LE, Noll G, Hannak M, Luscher TF. Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels. J Cardiovasc Pharamacol 2000;35:361-5
96. Vergoulas G, Miserlis G, Solonaki F, et al. Combined treatment of hypercholesterolemia of renal transplant allograft recipients with fluvastatin and gemfibrozil. Transplant Int 2000;13 Suppl 1:S64-S67
97. Wierzbicki AS, Lumb PJ, Cheung J, Crook MA. Experience with simvastatin-fenofibrate combination therapy compared to simvastatin-cholestyramine therapy for familial hypercholesterolaemia. Q J Med 1997;90:631-4
98. Zambon D, Ros E, Rodriguez-Villar C, et al. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation. Metabolism 1999;48:47-54
99. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002;301:1042-51
100. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002;360:1155-62
101. Illingworth DR, O'Malley JP. The hypolipidemic effects lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia. Metabolism 1990;39:403-9
102. Wierzbicki AS, Reynolds TM. Familial hyperchylomicronaemia. Lancet 1997;348:1524
103. Wierzbicki AS, Reynolds TM, Crook MA. Usefulness of orlisat in the treatment of severe hypertriglyceridemia. Am J Cardiol 2002;89:229-30
104. Steiner G. Lipid intervention trials in diabetes. Diabetes Care 2000;23(Suppl 2):B49-53
105. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002;346:539-40
106. Sacks FM and Expert Group on HDL Cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002;90:139-43
107. Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000;101:477-84
108. MRC/BHF Heart Protection Study investigators. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
109. The post coronary artery bypass graft trial investigators. The effect of aggressive lowering of low density cholesterol levels and low dose anticoagulation on obstructive changes in saphenous vein coronary artery bypass grafts. N Engl J Med 1997;336:153-62
110. Wierzbicki AS, Mikhailidis DP. Beyond LDL-C - the importance of raising HDL-C. Curr Med Res Opin 2002;18:36-44
111. Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, anti-oxidant vitamins, or the combination for prevention of coronary disease. N Engl J Med 2001;345:1583-92
112. Taher TH, Dzavik V, Reteff EM, Pearson GGJ, Woloschuk BL, Francis GA. Tolerability of statin-fibrate and statin-nicacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. Am J Cardiol 2002;89:390-4
113. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidaemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002;162:1568-76
114. Ito MK. Niacin-based therapy for dyslipidaemia: past evidence and future advances. Am J Manag Care 2002;8:S315-S322
115. Guyton JR. Combination therapy for combined hyperlipidaemia. Curr Cardiol Rep 1999;1:244-50
116. Erkelens DW. Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia. Cardiology 1990;77(Suppl 4):33-8
117. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001;35:908-17
118. Farmer JA, Gotto AM. Currently available hypolipidaemic drugs and future therapeutic developments. Baillieres Clin Endocrinol Metab 1995;9:825-47
119. Steinmetz KL. Colesevelam hydrochloride. Am J Health Syst Pharm 2002;59:932-9
120. Wong NN. Colesevelam: a new bile acid sequestrant. Heart Dis 2001;3:63-70
121. Miettinen TA. Cholesterol absorption inhibition: a strategy for cholesterol lowering therapy. Int J Clin Pract 2001;55:710-16
122. Kosoglou T, Meyer I, Veltri EP, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002;54:309-19
123. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministration wdth atorvastatin or simvastatin in patients with homozygous hypercholesterolemia. Circulation 2002;105:2469-75
124. Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 2001;85:544-8
125. Tanne D, Karen-Morag N, Graff E, Goldbourt U. Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) registry: high triglycerides constitute an independent risk factor. Circulation 2001;104:2892-7
126. Karen-Morag N, Tanne D, Graff E, Goldbourt U. Low and high density lipoprotein cholesterol and ischemic cerebrovascular disease: the Bezafibrate Infarction Prevention registry. Arch Intern Med 2002;162:993-9
127. Rizos E, Mikhailidis DP. Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention? Cardiovasc Res 2001;52:199-207
128. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. JAMA 2001;285:1711-18
129. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, et al. Treatment with Atorvastatin to the National Cholesterol Educational Program Goals versus Usual Care in Secondary Coronary Heart Disease Prevention. The GREek Atorvastatin and Coronary-heartdisease Evaluation (GREACE) Study. Curr Med Res Opin 2002;18:220-8
130. Mikhailidis DP, Wierzbicki AS. Editorial Comment: The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:215-19
131. Rizos E, Mikhailidis DP. Are high-density lipoprotein and triglyceride levels important in secondary prevention impressions from the BIP and VA-HIT trials. Int J Cardiol 2002;82:199-207
132. Wierzbicki AS. Lipid-lowering. Another method of reducing blood pressure? J Hum Hypertens 2002;16:753-60